Interventions Supporting Long-term Adherence aNd Decreasing cardiovascular events (ISLAND): Pragmatic randomized trial protocol - 01/08/17
, J-D Schwalm, MD, MSc, FRCP(C) d, e, Holly O. Witteman, PhD f, g, h, i, Justin Presseau, PhD j, k, Monica Taljaard, PhD j, k, Tara McCready, PhD, MBA e, Beth Bosiak, BComm, BA, MSc b, Jennifer Cunningham e, Shelley Smarz, MA, MBA e, Laura Desveaux, PhD, MScPT b, Jack V. Tu, MD, PhD c, l, m, Clare Atzema, MD, MSc, FRCPC c, m, n, Garth Oakes, PhD o, Wanrudee Isaranuwatchai, PhD p, Sherry L. Grace, PhD q, r, R. Sacha Bhatia, MD,MBA c, m, s, t, Madhu Natarajan, MD, MSc d, e, Jeremy M. Grimshaw, MBChB, PhD j, uAbstract |
Background |
Guidelines recommend cardiac rehabilitation and long-term use of cardiac medications for most patients who have had a myocardial infarction (MI), but adherence to these secondary prevention treatments is suboptimal.
Methods |
This is a multicenter, pragmatic, 3-arm randomized trial. Eligible patients (n = 2,742) with obstructive coronary artery disease are randomized post-MI to usual care or 1 of 2 intervention arms. Patients in the first intervention arm receive mail-outs sent on behalf of their cardiologist at 4, 8, 20, 32, and 44 weeks post-MI; content is designed to address determinants of adherence and facilitate discussion between the patient and their health care team. Patients in the second intervention arm receive mail-outs plus automated interactive voice response system telephone calls 2 weeks after each letter, as well as a telephone call by trained lay health workers if the interactive voice response system identifies challenges with adherence. Outcomes are assessed 12 months post-MI via patient self-report and administrative data sources. Co-primary outcomes are adherence to cardiac medications and completion of cardiac rehabilitation. Secondary outcomes include cardiovascular events and mortality. An embedded, theory-informed process evaluation will explore the mechanism of action; an economic evaluation is also planned.
Conclusions |
We describe a complete program evaluation of a highly pragmatic, health-system intervention to support adherence to recommended treatments. Research ethics boards approved waiver of consent for patients enrolled in the trial with provision of multiple opportunities to opt out and a debrief at the time of outcome assessment. The methods used here may provide a model for similar interventions.
Le texte complet de cet article est disponible en PDF.Abbreviations : CCN, CR, HAPA, ICES, IVRS, LHW, MI, PHRI
Plan
| RCT No. NCT02382731 |
|
| Trial registration: ClinicalTrials.gov: NCT02382731 |
|
| Trial funding: Ontario Ministry of Health and Long Term Care and the Canadian Institutes of Health Research's Strategy for Patient Oriented Research, through the Ontario Strategy for Patient Oriented Research Support Unit. |
|
| N.M.I. is supported by New Investigator Awards from the Canadian Institutes of Health Research and the Department of Family and Community Medicine at the University of Toronto. J.M.G. is supported by a Tier 1 Canada Research Chair in Health Knowledge Transfer and Uptake. H.O.W. is supported by a Fonds de recherche du Québec-Santé Resaerch Scholar Junior 1 career development award. |
Vol 190
P. 64-75 - août 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
